Neuropilin‐2 and its ligand VEGF‐C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients
暂无分享,去创建一个
A. Hartmann | H. Taubert | S. Wach | B. Wullich | C. Rödel | R. Sauer | R. Fietkau | G. Baretton | B. Keck | S. Schellenburg | M. Muders | F. Kunath | S. Bertz | O. Ott | K. Datta | C. Weiss | F. Krause | A. Hartmann | S. Zeiler | P. Hönscheid | Gustavo Baretton | Helge Taubert | B. Wullich | Sven Wach
[1] C. Korch,et al. Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition. , 2013, Cancer research.
[2] L. Häberle,et al. Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy , 2013, World Journal of Urology.
[3] H. Sandler,et al. Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival. , 2013, The oncologist.
[4] E. Giraudo,et al. The role of semaphorins and their receptors in vascular development and cancer. , 2013, Experimental cell research.
[5] M. Muders,et al. Angiogenic growth factor axis in autophagy regulation , 2013, Autophagy.
[6] J. Battermann,et al. Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] P. Nelson,et al. VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. , 2012, Cancer discovery.
[8] Y. Glinka,et al. Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NF-κB activation and tumor sphere formation. , 2012, Biochemical and biophysical research communications.
[9] Y. Glinka,et al. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity , 2012, Oncotarget.
[10] A. Mercurio,et al. Neuropilin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling , 2012, Journal of Cell Science.
[11] V. Kataja,et al. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] L. Häberle,et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. , 2011, Anticancer research.
[13] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[14] D. Tindall,et al. Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. , 2009, Cancer research.
[15] C. Rödel,et al. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. , 2009, International journal of radiation oncology, biology, physics.
[16] R. Cheney,et al. Prognostic significance of neuron-associated protein expression in non-muscle-invasive urothelial bladder cancer , 2009, Journal of Clinical Pathology.
[17] T. Sanke,et al. Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression , 2009, BMC Cancer.
[18] Ling Wang,et al. Targeting GIPC/Synectin in Pancreatic Cancer Inhibits Tumor Growth , 2009, Clinical Cancer Research.
[19] L. Ellis,et al. Neuropilin-2–Mediated Tumor Growth and Angiogenesis in Pancreatic Adenocarcinoma , 2008, Clinical Cancer Research.
[20] F. Peale,et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. , 2008, Cancer cell.
[21] J. Dunst,et al. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. , 2008, International journal of radiation oncology, biology, physics.
[22] L. Ellis,et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. , 2008, Journal of the National Cancer Institute.
[23] X. Zu,et al. Vascular endothelial growth factor‐C expression in bladder transitional cell cancer and its relationship to lymph node metastasis , 2006, BJU international.
[24] D. Mukhopadhyay,et al. Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma. , 2006, Cancer research.
[25] I. Giannopoulou,et al. Evaluation of the vascular endothelial growth factor (VEGF)-C role in urothelial carcinomas of the bladder. , 2006, Anticancer research.
[26] J. Dunst,et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Parmar,et al. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. , 2005, European urology.
[28] C. Vale. Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .
[29] Wentian Li,et al. Copyright © American Society for Investigative Pathology Gene Discovery in Bladder Cancer Progression using cDNA Microarrays , 2022 .
[30] J. Dunst,et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] K. Guru,et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. , 2013, European urology.
[32] D. Tindall,et al. Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. , 2013, Cancer research.
[33] Franklin Peale,et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. , 2007, Cancer cell.